Ulrea-pvs-np

Phase 1

KKyushu University

Ulrea-pvs-np is one of 4 therapeutic programs targeting Retinitis Pigmentosa (RP). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Retinitis Pigmentosa (RP)Not yet recruiting

Retinitis Pigmentosa (RP)Phase 1

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Retinitis Pigmentosa (RP)

#DrugCompanyPhaseTrials

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Phase 3

1 2

NPI-001

NNacuity Pharmaceuticals, Inc.

Phase 3

1 3

Intravitreal Injection of Ultevursen

LLaboratoires Thea

Phase 2

2 4

Ulrea-pvs-np

KKyushu University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Retinitis Pigmentosa (RP)

NCT07774975

Clinical

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

Investigator-initiated Phase 1 Clinical Trial to Evaluate the Safety of Pitavastatin PLGA Nano-particle in Patients With Retinitis Pigmentosa

Not yet recruiting·KKyushu University·Phase 1·NCT07774975·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ulrea-pvs-np. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ulrea-pvs-np. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kyushu University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: KKyushu University

Ulrea-pvs-np

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

References

Drug Info

Quick Facts

Related News